|
|
|
|
|
(1) |
|
|
(2) |
|
|
(3) |
Centers for Disease Control and Prevention, Antimicrobial Resistance in Healthcare Settings | CDC Infection Control in Healthcare; available at http://www.cdc.gov/ncidod/dhqp/ar.html, accessed 3/25/2007.
|
|
(4) |
Levy, Stuart, The Challenge of Antibiotic Resistance, Scientific American, Mar;278(3):46-53 (1998).
|
(5) |
|
|
(6) |
Center for Diesease Control and Prevention Division of Tuberculosis Elimination, "Questions and Answers about TB 2005;" available at http://www.cdc.gov/tb/faqs/default.htm, accessed 3/25/2007.
|
|
(7) |
Levy, S and Marshall B. Antibacterial resistance worldwide: causes, challenges, and responses. Nature Medicine Supplement. (2004) 12, S122-9.
|
|
(8) |
|
|
(9) |
Levy, Stuart B., The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle, Boston: Perseus Books, 2002. |
(10) |
|
|
(11) |
Wenzel, Richard P, "The Antibiotic Pipeline - Challenges, Costs, and Values," The New England Journal of Medicine. (2004) 351(6): 523-526.
|
(12) |
|
|
(13) |
Chain, E, Florey, HW, Gardner, AD, Heatley, NG, Jennings, MA, Ewing, JO, and Sanders, AG, Penicillin as a chemotherapeutic agent. The Lancet. (1940) 2, 226-228.
|
|
(14) |
Florey, ME, and Florey, HW, General and local administration of penicillin. The Lancet. (1943) 1, 387-397.
|
|
|
|
|